Close Menu

NEW YORK – Guardant Health said this week that it still believes it can complete recruitment for its ongoing, prospective ECLIPSE study of its colorectal cancer early detection assay within a previously stated timeline of about 24 months.

This is despite significant changes caused by the COVID-19 pandemic in recent months that have led to fewer patients being offered routine procedures like colonoscopies, which are an eligibility requirement for the study.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.